Adrulipase alfa is a Recombinant Enzyme owned by First Wave BioPharma, and is involved in 6 clinical trials, of which 5 were completed, and 1 is planned.
Adrulipase alfa enhances the functioning of the pancreas in pancreatic exocrine insufficiency. Lipase is an enzyme that the body uses to break down fats. Bile breaks down the large fat molecule to tiny droplets which provide lipase with an enormously increased surface to work on. This action takes place in the small intestine and the lipase involved here is a part of the pancreatic secretion.
The revenue for Adrulipase alfa is expected to reach a total of $166m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Adrulipase alfa NPV Report.
Adrulipase alfa Overview
Adrulipase alfa is under development for the treatment of exocrine pancreatic insufficiency (EPI) in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). It is administered as a oral capsule. The therapeutic candidate is an autologous Yarrowia lipolytica recombinant lipase. It is developed based on recombinant DNA technology. It was also under development for the treatment of malabsorption syndrome.
First Wave BioPharma Overview
First Wave BioPharma, formerly AzurRx BioPharma, is a development-stage biopharmaceutical company that focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development include MS1819 a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). MS1819 completed the phase IIa trial in partnership with Mayoly which is a European Pharmaceutical company. Its pre-clinical products include AZX1103 and AZX1101 which is a recombinant beta-lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. First Wave BioPharma is headquartered in Brooklyn, New York, the US.
The operating loss of the company was US$59.1 million in FY2021, compared to an operating loss of US$26.8 million in FY2020. The net loss of the company was US$58.5 million in FY2021, compared to a net loss of US$32.7 million in FY2020.
Quick View – Adrulipase alfa
|Highest Development Stage|